TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1 / Line 1-2	Title
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page 1/ Line 5-Page 2/ Line 9	Abstract
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page 3 / Line 2-4, Page 3 / Line 20-Page 4 / Line 1, Page 4 / Line 4-7	Introduction / Paragraph 1-2
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page 4 / Line 8-12	Introduction / Paragraph 3
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page 4 / Line 17-19	Study patients / Paragraph 1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page 4 / Line 17-19	Study patients / Paragraph 1
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page6 / Line 14-21	CTA techniques
	5b	D;V	Describe eligibility criteria for participants.	Page 4 / Line 21-Page 5 / Line 7	Study patients / Paragraph 2-3
	5c	D;V	Give details of treatments received, if relevant.	N/A	There are no treatments received in our study.
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page 5 / Line 15-19	Classification of cerebral ischemia symptoms
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	Page 5 / Line 18-19	Classification of cerebral ischemia symptoms

Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page 7/ Line 10-Page 9/ Line 15	Traditional CTA plaque analysis; Image segmentation, feature extraction, selection and model building/Paragraph 1-3
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Page 7 / Line 10-14, Page 10 / Line 7-8	Traditional CTA plaque analysis; Intraobserver and interobserver agreement of radiomics features
Sample size	8	D;V	Explain how the study size was arrived at.	Page 4 / Line 17-Page 5 / Line 9	Study patients / Paragraph 1-4

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	N/A	There is no missing data
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page 8 / Line 22-Page 9 / Line 15; Page 10 / Line 20-Page 11 / Line 3	Image segmentation, feature extraction, selection and model building / Paragraph 2-3; Statistical analysis
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page 9 / Line 17-21; Page 12 / Line 20-Page 13 / Line 15	Image segmentation, feature extraction, selection and model building / Paragraph 4；Selection of radiomics features/ Paragraph 1-2
	10c	V	For validation, describe how the predictions were calculated.	Page 9 / Line 19-21; Page13 / Line 20; Page 14 / Line 2-3, 8,14.	Image segmentation, feature extraction, selection and model building / Paragraph 4; Building models/ Paragraph 2-3.
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page 10 / Line 1-2	mage segmentation, feature extraction, selection and model building / Paragraph 4
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A	There is no model updating in our study
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	N/A	There is no risk group in our study
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Table 3	Table 3
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	The study flow chart (Figure 3)	The study flow chart (Figure 3)
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Table 1	Table 1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Table 2	Table 2
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	Table 2	Table 2
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	N/A	The current study was not designed as matched studies.

Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Page 12 / Line 3-4； Page13 / Line 20; Page 14 / Line 2-3, 8,14.	Assessment of carotid plaques on CTA; Building models/Paragraph 2-3.
	15b	D	Explain how to the use the prediction model.	N/A	The current study was not designed as matched studies.
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Table 3	Table 3
Model- updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A	The current study was not designed as matched studies.
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page 18 / Line 22-Page 19 / Line 9	Discussion / Paragraph 7

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	N/A	Our study had only internal validation and no independent external validation.
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page 17 / Line 7-10; Page 18 / Line 1-3 Page 18 / Line 15-21	Discussion / Paragraph 4-6
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page 15 / Line 3-7	Discussion / Paragraph 1
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	N/A	Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page 19 / Line 16-17	Acknowledgments / Funding

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: https://dx.doi.org/10.21037/qims-23-158
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.